Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Only half of eligible heart failure patients receive implantable devices

A study of heart failure patients who meet national guidelines for devices that stabilize and strengthen the heart's electrical system found that only half of eligible patients received the devices.

19 Dec 2009

InHealth to further understand socioeconomic impact of medical devices and diagnostics

As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.

19 Dec 2009

Medicare expenditures less for POHs compared to non-POHs, says new study

The cost to Medicare of a patient receiving treatment at a physician owned and operated hospitals is "4.6 to 6.00% lower" than hospitals not run by physicians, according to a new study by Oxford Outcomes, an internationally respected research agency.

18 Dec 2009

Study results of Impella 2.5 circulatory assist device in high-risk PCI procedures published

Results from the Europella registry, evaluating the safety and feasibility of the Abiomed, Inc. Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention (PCI) procedures have been published in the December 15 issue of the Journal of the American College of Cardiology (JACC).

18 Dec 2009

Treprostinil drug reduces breathlessness in PAH patients, says study

Patients with a rare, deadly disease that mostly affects young women felt a dramatic reduction in breathlessness using an approved drug, according to study results published online today in The Journal of Heart and Lung Transplantation.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

Medifacts International announces new innovations in the use of telemedicine in clinical trials

MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of noninvasive cardiovascular diagnostic services, today announced that they are once again leading the Cardiovascular Safety Services marketplace in innovation, expertise, and execution - this time with new innovations in the use of telemedicine, T-SMBP (Telemonitoring Self Measured Blood Pressure), in clinical trials.

17 Dec 2009

ODAC to review Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

17 Dec 2009

Group of drugs used to treat heart failure shows promise for fighting colon cancer

Scientists in Sweden are reporting for the first time that a group of drugs used to treat heart failure shows promise for fighting colon cancer. The study is in ACS' Journal of Natural Products, a monthly publication. Colon cancer is the third most common cancer in the United States, with more than 150,000 cases diagnosed in the U.S. each year.

17 Dec 2009

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.

15 Dec 2009

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Geron Corporation today announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron’s request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 (the ‘876 patent) owned by Novocell, Inc.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

MHI launches new research program in heart failure

The Montreal Heart Institute (MHI) and its Foundation (MHIF) launched today the Carolyn and Richard J. Renaud Research Chair in Heart Failure, the first of its kind in Québec.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Changes to NCQA's disease management Accreditation and Certification standards released

The National Committee for Quality Assurance (NCQA) today released changes to its disease management Accreditation and Certification requirements, adding voluntary performance reporting for five chronic conditions.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Study finds widespread variations in CRT use for patients with severe heart failure

Most patients with heart failure likely to benefit from a pacemaker including the capacity for cardiac resynchronization therapy (CRT) do not receive such an implantable device, reports a national study in the December 2009 issue of the American Heart Journal.

14 Dec 2009

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

The Visiting Nurse Association (VNA) of Greater Philadelphia is expanding its traditional home health and specialty services to patients who reside in lower Bucks County.

14 Dec 2009

Heart Failure News and Research

Further Reading

Only half of eligible heart failure patients receive implantable devices

InHealth to further understand socioeconomic impact of medical devices and diagnostics

Medicare expenditures less for POHs compared to non-POHs, says new study

Study results of Impella 2.5 circulatory assist device in high-risk PCI procedures published

Treprostinil drug reduces breathlessness in PAH patients, says study

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Medifacts International announces new innovations in the use of telemedicine in clinical trials

ODAC to review Cell Therapeutics' NDA for pixantrone

Group of drugs used to treat heart failure shows promise for fighting colon cancer

Low plasma CETP activity associated with increased risk of heart disease, says study

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Geron’s request for declaration of interference regarding Novocell' U.S. Patent No. 7,510,876 granted

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

MHI launches new research program in heart failure

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Changes to NCQA's disease management Accreditation and Certification standards released

Pfizer announces results from studies evaluating neratinib

Combination therapy improves overall survival in women with advanced breast cancer

Study finds widespread variations in CRT use for patients with severe heart failure

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News